1. Home
  2. ENTX vs MDBH Comparison

ENTX vs MDBH Comparison

Compare ENTX & MDBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • MDBH
  • Stock Information
  • Founded
  • ENTX 2010
  • MDBH 1997
  • Country
  • ENTX Israel
  • MDBH United States
  • Employees
  • ENTX N/A
  • MDBH N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • MDBH
  • Sector
  • ENTX Health Care
  • MDBH
  • Exchange
  • ENTX Nasdaq
  • MDBH Nasdaq
  • Market Cap
  • ENTX 67.2M
  • MDBH 66.8M
  • IPO Year
  • ENTX 2018
  • MDBH 2023
  • Fundamental
  • Price
  • ENTX $2.25
  • MDBH $6.12
  • Analyst Decision
  • ENTX Strong Buy
  • MDBH
  • Analyst Count
  • ENTX 1
  • MDBH 0
  • Target Price
  • ENTX $10.00
  • MDBH N/A
  • AVG Volume (30 Days)
  • ENTX 54.3K
  • MDBH 12.5K
  • Earning Date
  • ENTX 11-08-2024
  • MDBH 11-12-2024
  • Dividend Yield
  • ENTX N/A
  • MDBH N/A
  • EPS Growth
  • ENTX N/A
  • MDBH N/A
  • EPS
  • ENTX N/A
  • MDBH N/A
  • Revenue
  • ENTX $99,000.00
  • MDBH $1,937,885.00
  • Revenue This Year
  • ENTX N/A
  • MDBH N/A
  • Revenue Next Year
  • ENTX N/A
  • MDBH N/A
  • P/E Ratio
  • ENTX N/A
  • MDBH N/A
  • Revenue Growth
  • ENTX 607.14
  • MDBH N/A
  • 52 Week Low
  • ENTX $0.52
  • MDBH $5.78
  • 52 Week High
  • ENTX $3.35
  • MDBH $13.25
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 68.35
  • MDBH 39.25
  • Support Level
  • ENTX $2.02
  • MDBH $6.00
  • Resistance Level
  • ENTX $2.28
  • MDBH $6.27
  • Average True Range (ATR)
  • ENTX 0.17
  • MDBH 0.29
  • MACD
  • ENTX 0.04
  • MDBH -0.11
  • Stochastic Oscillator
  • ENTX 77.01
  • MDBH 8.07

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About MDBH MDB Capital Holdings LLC common

MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.

Share on Social Networks: